Clinical trials: Type 2 Diabetes (T2DM)
Type 2 Diabetes Mellitus
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.
- Trial name
- AWARD-CHN3 (NCT04591626)
- Testing
- Dulaglutide, Insulin Glargine
- Where
- 27 sites in China
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus (T2DM)
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with type 2 diabetes mellitus who have inadequate glycemic control while receiving…
- Trial name
- NCT07628985
- Testing
- Bofanglutide, Semaglutide
- Where
- 7 sites in Mexico
- Volunteers
- 374 people
- Sponsor
- Carnot Laboratories
Diabetes
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Glargine U100 with Non-Insulin Antidiabetic Agents in Insulin-naive Subjects with Type 2…
- Trial name
- NCT06767735
- Testing
- GZR4, Insulin Glargine U100
- Where
- China
- Volunteers
- 580 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Type 2 Diabetes
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of HS-20094 injection in subjects with type 2 diabetes who have inadequate glycemic control with…
- Trial name
- NCT07156500
- Testing
- HS-20094 Injection
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects
The purpose of this trial is to demonstrate that dextromethorphan (DXM) and amantadine compared to placebo exert blood glucose (BG) lowering effects following an oral glucose tolerance test (OGTT) in male subjects with T2DM.
- Trial name
- DXM/AMT (NCT01441986)
- Testing
- Dextromethorphan hydrobromide, Amantadine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese…
- Trial name
- NCT06628362
- Testing
- Enicepatide
- Where
- 70 sites in United States, Argentina and 4 more
- Volunteers
- 447 people
- Sponsor
- Carmot Therapeutics, Inc.
T2DM (Type 2 Diabetes Mellitus)
Single Escalating Dose Study Of HSK7653 In Healthy Subjects
To evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of single dose of HSK7653 tablets in healthy adult subjects, and to identify the metabolites of HSK7653 in healthy adult subjects
- Trial name
- NCT05983289
- Testing
- HSK7653
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Type 2 Diabetes
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
This trial is aimed to investigate the safety, tolerability, PK and PD of multiple subcutaneous injections of IBI362 in Chinese patients with type 2 diabetes who have poor glycemic control after lifestyle or metformin intervention
- Trial name
- NCT04466904
- Testing
- IBI362, Dulaglutide
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
NAFLD, Diabetes Mellitus, Type 2
Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 703802 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Conditions
- NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
- Trial name
- NCT03371355
- Testing
- ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
- Where
- 42 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Akcea Therapeutics
Type 2 Diabetes Mellitus
Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin
This is a 24-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group, phase 3 study designed to evaluate if the safety and efficacy of dapagliflozin 5 mg or 10 mg added to saxagliptin 5 mg…
- Trial name
- NCT03608358
- Testing
- Dapagliflozin 10 mg, Dapagliflozin 5 mg, Saxagliptin 5 mg
- Where
- 4 sites in Thailand, Vietnam
- Volunteers
- 41 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)
A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable insulin alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01590797
- Testing
- Sitagliptin, Insulin, Metformin
- Volunteers
- 467 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus (T2DM)
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.
- Trial name
- NCT06660173
- Testing
- Maridebart Cafraglutide
- Where
- 96 sites in United States, Austria and 12 more
- Volunteers
- 409 people
- Sponsor
- Amgen
Type-2 Diabetes Mellitus
A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study)
The purpose of this study is to assess the safety, tolerability and effectiveness of RF vapor ablation of the proximal intestinal mucosa.
- Trial name
- RESTORE-1 (NCT07355270)
- Testing
- RF Vapor Ablation
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aqua Medical, Inc.
Type 2 Diabetes Mellitus
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
This study evaluated the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin.
- Trial name
- NCT04029480
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Insulin
- Where
- 104 sites in United States, Belgium and 20 more
- Volunteers
- 166 people
- Sponsor
- Merck Sharp & Dohme LLC
T2DM (Type 2 Diabetes Mellitus)
Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393
A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-393 0.5/100/1000 mg under fed condition
- Trial name
- NCT04706286
- Testing
- CKD-501, D759, D150, CKD-393 0.5/100/1000 mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
This study is a multicenter, randomized, double-blind (with open-label dose levels and active comparator), parallel-group, placebo- and active-controlled Phase 2 clinical trial aimed at evaluating the efficacy, safety…
- Trial name
- NCT07109700
- Testing
- HDM1005 1, HDM1005 2, HDM1005 3
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus (T2DM), Overweight or Obese
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
The purpose of this study is to assess how fast BGM0504 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
- Trial name
- NCT06929156
- Testing
- BGM0504
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Diabetes Mellitus, Type 2
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
The primary objective of this study is to determine if there will be a greater mean reduction from baseline in glycated hemoglobin (HbA1c) achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin or…
- Trial name
- NCT03199053
- Testing
- Dapagliflozin, Saxagliptin
- Where
- 122 sites in United States, Argentina and 21 more
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin
The primary objective of the study is to investigate cardiovascular safety of gemigliptin by evaluating the time until patients report with major adverse cardiovascular events (MACE) in T2DM patients treated with gemigliptin.
- Trial name
- NCT02290301
- Testing
- gemigliptin
- Where
- South Korea
- Volunteers
- 5,180 people
- Sponsor
- LG Life Sciences
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to examine the effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus.
- Trial name
- IRAK4 (NCT07433062)
- Testing
- AZD6793
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- AstraZeneca